Greenwich LifeSciences Interview to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
ACCESSWIRE•13/11/2026•09:00 ET
1
Key Highlights
- ➤GLSI-100 cut breast cancer recurrence approximately 80% in Phase IIb trial
- ➤Phase III FLAMINGO-01 showed strong immune responses and early recurrence trends
- ➤Non-HLA-A02 cohort showed approximately 80% recurrence reduction in preliminary observations
- ➤Broader eligibility could double target population from 44,000 to 88,000 patients
- ➤Greenwich operates approximately 160 clinical sites across the United States and Europe
Expert Statements
Snehal Patel, CEO of Greenwich LifeSciences
“GLSI-100 combines the GP2 peptide with GM-CSF to stimulate the immune system to recognize and eliminate recurring cancer cells following surgery and standard antibody treatment.”
Snehal Patel, CEO of Greenwich LifeSciences
“The open-label, non-HLA-A02 patient cohort has shown an approximately 80% reduction in recurrence based on the Company's preliminary observations, consistent with results from the earlier Phase IIb study.”
ORLANDO, FL / ACCESS Newswire / November 13, 2026 / RedChip Companies will air an interview with Greenwich LifeSciences, Inc. (NASDAQ:GLSI) on the RedChip Small Stocks, Big Money™ show, a sponsored television program airing on Bloomberg TV this Saturday, November 14, at 7:00 p.m. Eastern Time (ET), and on CNBC this Sunday, November 15, at 11:30 a.m. ET. Bloomberg TV is available in an estimated 73 million homes across the United States, and CNBC is available in approximately 90 million U.S. households.
Access the interview in its entirety at: https://www.redchip.com/assets/access/glsi_access
Get started
Create a free account to read the full story.